3 High-Yield Dividend Stocks to Buy in 2018
Dividend investors on the hunt for above average income opportunities may want to place a heavy emphasis on pharmaceutical stocks next year. Despite the political turmoil surrounding the Affordable Care Act (aka Obamacare), the pharmaceutical industry is still growing at a healthy clip, thanks primarily to the introduction of several game-changing new therapies for cancer and rare diseases over the past few years.
Within the realm of Big Pharma, for instance, AstraZeneca (NYSE: AZN), Pfizer (NYSE: PFE), and Sanofi (NYSE: SNY) all offer juicy dividend yields that exceed 3% at the moment, as well as broadly positive outlooks from both a near -- and long-term perspective. Armed with this insight, let's consider why these three pharmaceutical giants may be worth owning in 2018, and beyond.
Image source: Getty Images.
Source: Fool.com
Sanofi S.A. ADR Stock
Currently there is a rather positive sentiment for Sanofi S.A. ADR with 4 Buy predictions and 0 Sell predictions.
As a result the target price of 49 € shows a positive potential of 28.27% compared to the current price of 38.2 € for Sanofi S.A. ADR.
